[Sclerosing rhabdomyosarcoma of the parotid gland: Unusual location of a rare mesenchymal tumor].
Rhabdomyosarcome sclérosant de la parotide : localisation inhabituelle d’une tumeur mésenchymateuse rare.
Histologie
Histopathology
Parotid gland
Parotide
Prognosis
Pronostic
Rhabdomyosarcome sclérosant
Sclerosing rhabdomyosarcoma
Journal
Annales de pathologie
ISSN: 0242-6498
Titre abrégé: Ann Pathol
Pays: France
ID NLM: 8106337
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
04
08
2016
revised:
25
05
2020
accepted:
27
05
2020
pubmed:
28
7
2020
medline:
16
10
2021
entrez:
28
7
2020
Statut:
ppublish
Résumé
Rhabdomyosarcoma is a malignant mesenchymal tumour with skeletal muscle differentiation. Its sclerosing variant is a rare entity, which is described in the latest WHO edition of soft tissues in association with the spindle cell subtype, with which it shares clinical, morphological and cytogenetic features. Cytogenetic advances have allowed a prognostic approach to fusiform/sclerosing cell rhabdomyosarcoma by individualizing 3 different genomic prognostic groups. The parotid location of sclerosing rhabdomyosarcoma is exceptional with only two reported cases in the literature. It can pose a diagnostic challenge because of its rarity and histological similarities with other malignancies. We report the third case of sclerosing rhabdomyosarcoma of the parotid gland, which occurred in a 7-year old girl, who had consulted for a painless swelling of the parotid region of 4 months duration. Gross examination of the partial parotidectomy demonstrated an ill-circumscribed 35×30mm, firm and white glistening tumor. Histologically, it was composed of cords and trabeculae of small round cells, with ovoid and often irregular nuclei. Mitoses were numerous. The cytoplasm was scanty and cell margins were unclear. Tumor cells were set in a prominent hyalinized matrix. Scattered rhabdomyoblastic-like tumor cells were noted. The diagnosis of sclerosing rhabdomyosarcoma was performed after the positive immunostaining with desmin, myogenin and smooth muscle actin. No cytogenetic or molecular studies were performed. The patient underwent adjuvant chemo and radiotherapy, without recurrences or distant metastases during the 8-year follow-up.
Identifiants
pubmed: 32713625
pii: S0242-6498(20)30160-7
doi: 10.1016/j.annpat.2020.05.007
pii:
doi:
Types de publication
Case Reports
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
123-128Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.